Never let them know how badly you need the deal

Published: Wed, 02/25/26

Updated: Fri, 02/27/26

February 25, 2026

TOGETHER WITH

Welcome back, Quota readers, and (hopefully) quota-achievers. This week’s issue brings with it more snow, more shoveling, but more after-shoveling snacks too. We’ll look at the history of the pharma sales rep, then give you your usual dose of fun. Sit back, relax, and enjoy!

NUMBER OF THE WEEK

76% of reps wish there were more transparency in how their sales compensation is calculated

Source: Salesforce

SALES ROUNDUP

Here’s what’s happening in the sales world this week:

A family in North Georgia recently recounted how a typical afternoon turned into a $90,000 nightmare. According to a report by WSB-TV, a car salesman allegedly targeted an elderly man living with dementia and convinced him to buy a high-priced pickup truck he was in no condition to negotiate for. But, the family says the ordeal did not end there. After news of the scam broke, the dealership reached a settlement with the victim’s family. But, the family says, the same salesman continued to call the elderly man in an effort to convince him to do another deal. You can read more about it here.
A Florida man has been arrested for shooting a door-to-door salesman who was prospecting in his neighborhood. On Feb. 18, deputies responded to a 911 call and found a man with multiple gunshot wounds to his lower body. He was taken to a local hospital with non-life-threatening injuries. Detectives believe the victim and his female co-worker were soliciting telecommunication products and services door-to-door when Reginald McGee, 38, became verbally aggressive. Following a confrontation, McGee allegedly shot the victim. You can read more about it here.

FEATURE

Why the 90s Were The Golden Age of the Pharma Rep

In the late 1990s, a pharmaceutical sales rep could walk into a doctor’s office carrying catered lunch, a stack of glossy clinical studies, and a briefcase full of drug samples worth thousands of dollars. The waiting room might have been full, but the rep knew the routine. Drop off food for the staff. Catch the physician between patients. Leave behind samples that would quietly shape prescribing habits.

At the peak of the boom, pharmaceutical sales was one of the most lucrative and aggressively scaled sales machines in America.

By 2006, the industry employed roughly 100,000 sales reps in the United States alone, nearly one rep for every six practicing physicians at the time. Companies were spending billions annually on marketing to physicians. A 2007 study in the New England Journal of Medicine estimated that the pharmaceutical industry was spending close to $30 billion a year on drug promotion, with a significant share directed at doctors.

Access Was the Product

Pharma reps were selling into one of the most protected buyer environments in the country. Doctors are trained experts with limited time, high liability, and little patience for fluff. The product was complex. The regulatory landscape was strict. Direct-to-consumer advertising was growing, but prescriptions still required physician approval.

Access became the advantage. Reps learned to navigate office hierarchies. Front desk staff mattered. Nurses mattered. Office managers mattered. A rep who understood the ecosystem of a clinic could secure those crucial minutes with doctors that competitors couldn’t.

And those minutes mattered. A landmark study published in JAMA Internal Medicine found that even small industry payments to physicians were associated with higher prescribing rates of the sponsoring company’s drugs. In some cases, a single sponsored meal correlated with measurable changes in prescription behavior. The meal itself was rarely the point. The repetition was. Familiar names feel safer than unfamiliar ones. In medicine, perceived safety drives decisions.

The Scale of the Machine

During the 1990s and early 2000s, pharma companies were launching blockbuster drugs at a rapid pace. Antidepressants, cholesterol medications, painkillers, and lifestyle drugs flooded the market. To win share, companies expanded their field forces dramatically.

Territories were mapped tightly. Reps were assigned to specialties. Compensation plans were linked to prescription lift in their region. It was a pure sales machine.

One 2004 Government Accountability Office report noted that pharmaceutical marketing expenditures more than doubled between the mid-1990s and early 2000s. Detailing, the industry term for in-person physician visits, represented a major portion of that spending.

The Cultural Peak

For a time, the pharma rep became a cultural archetype. And the industry rewarded the top performers lavishly—incentive trips, bonuses, and recognition programs were common.

Then scrutiny grew.

Journalists and lawmakers began asking how much influence marketing dollars had on medical decision-making. ProPublica launched its “Dollars for Docs” investigation, publishing data on payments from drug companies to physicians. The findings were uncomfortable. Financial relationships between industry and doctors were widespread. While many were for speaking engagements or research, the optics shifted public perception.

Then, congress responded.

The Sunshine Era

In 2010, the Physician Payments Sunshine Act was passed as part of the Affordable Care Act. The law required pharmaceutical and medical device companies to publicly disclose payments and transfers of value made to physicians and teaching hospitals.

The result was the Open Payments database, a searchable public record of industry relationships. Suddenly, lunches, speaking fees, consulting agreements, and travel reimbursements were visible to anyone with an internet connection.

The field changed quickly. Gift policies tightened. Access to doctors narrowed. Large-scale hospitality programs faded. Headcounts declined. According to industry reports, the number of pharmaceutical sales reps in the United States fell significantly after the mid-2000s peak.

What Replaced the Boom

Today’s pharmaceutical sales landscape is more regulated and data-driven. Digital engagement supplements in-person visits. Compliance training is rigorous. The overt hospitality culture of the 1990s is largely gone.

But the core lesson of that golden era remains relevant to anyone in sales.
Access shapes outcomes. And structured field forces, when funded and incentivized aggressively, can move markets. The golden age of the pharma rep proved something that still holds true across industries. Influence is consistent, embedded, and reinforced over time.

And when enough money backs it, it can change an entire industry.

TOGETHER WITH I HOPE THIS EMAIL FINDS YOU NEVER

I Hope This Email Finds You Never is what you get when someone finally writes about work without the corporate BS.

4 stars on Amazon and packed with the real advice you need:

• How long you can milk being "new" before someone expects you to actually work
• The art of fake apologies that preserve your honor
• Strategic camera angles for maximum Zoom intimidation
• Kitchen politics and why eating someone's yogurt is literally a crime
• Calendar management that includes adequate crying time
• Writing your resignation letter when you've been resigned since day one

From Orientation (aka The Descent) to Working Remotely (wink wink) to Coworkers (your fellow inmates), this book covers everything you need to survive the modern workplace.

Warning: This book will not make you successful. But it might keep you sane.

BUY NOW

MEME OF THE WEEK

Source: Instagram -- Sales Humor

QUIZ

Which actor starred in the 2000 sales movie Boiler Room?

A. Josh Hartnett
B. Seth Green
C. Tobey Maguire
D. Giovanni Ribisi

SALES FAILS

Each week, we bring you the most cringe-worthy sales moments from across the web. To submit your sales fail story for consideration, click here. (Don't worry, you'll remain completely anonymous).

I was working my biggest deal of the quarter with a mid-sized enterprise account (I sell HR software). It had been in my pipeline for a couple of months and leadership kept asking about it on every forecast call. My manager called it our “anchor deal.” No pressure.
‍
We were late stage. Pricing had been discussed and we were starting to talk about onboarding timelines. It felt real. The buyer was engaged and asking practical questions about implementation instead of hypothetical ones. Somewhere in the middle of the call, I got a little too comfortable. I was trying to reinforce how excited we were to partner and said something along the lines of, “Honestly, this would be a huge win for us this quarter.”
‍
The second it came out of my mouth I knew I shouldn’t have said it. There was a short pause. Then the questions changed. He started asking about flexibility. About whether pricing was firm. About what else we could include. Suddenly there were a few more stakeholders who needed to weigh in.
‍
I still ended up closing the deal. But we got squeezed hard. We gave concessions we probably didn’t need to give and the timeline slipped into the following quarter. I basically told him how important the deal was to us… and he negotiated accordingly. Never again.

Anonymous

GRAPH OF THE WEEK

Source: LinkedIn Poll -- February 2026

WORTH A PEEK

Which industry pays more than tech sales? We admit to being a bit tech-focused, and it’s important to look outside our bubble every now and then. A recent Redditor asked for non-tech sales job recommendations, and over 200 people responded. Check out the conversation here.

ASK THE QUOTA

Want to submit a question and be featured in our advice column? Click here. (Don't worry, you'll remain completely anonymous).

Dear Quota Team,

I’m a regional sales rep for a specialty packaging manufacturer that supplies mid-sized food and beverage brands. We sell custom eco-friendly packaging — boxes, inserts, branded materials — the kind of stuff that sits on retail shelves.

At the start of this year, leadership raised prices by about 25% across most SKUs. We were told it reflects “premium positioning” and higher input costs. But raw material prices have stabilized, and from the customer’s perspective, the product hasn’t meaningfully changed.

Now I’m on renewal calls with long-time clients who are pulling up last year’s invoices and asking what justifies the jump. I don’t have a clean answer. I understand protecting margin. But it feels like I’m being asked to defend something I didn’t decide and can’t clearly explain. How do I handle this without damaging relationships I’ve spent years building?

Expensive in Location Withheld

----

Dear Transparent,

You don’t sell a price increase by pretending nothing has changed. If input costs aren’t the full story, don’t hide behind them. Anchor the conversation in business realities: supply chain volatility, capacity constraints, long-term partnership stability. Mature companies adjust pricing to protect reliability. That’s defensible. “Premium positioning” alone isn’t.

More importantly, acknowledge the increase directly. Customers respect clarity more than spin. “Yes, prices are up. Here’s why, and here’s what it protects for you.” Then shift to outcomes: reduced waste, brand consistency, on-time fulfillment. If leadership can’t articulate the logic, push internally for clearer talking points. You don’t need to believe in every decision. But you do need a story that preserves trust.

Quiz Answer: D. Giovanni Ribisi starred in the 2000 sales movie, Boiler Room.

How did you like today's story?

Today's email was written by Ken Kupchik and Steve Rado.

Was this email forwarded to you? Sign up here.

Advertise with us

Books

QUOTA MEDIA LLC

651 N. Broad Street., Suite 206
Middletown DELAWARE (DE) 19709
USA

Unsubscribe | Change Subscriber Options